Review Article

Dabigatran and Dental Procedures in Patients with High Risk Bleeding

Abstract

Background: Management of patients with high risk of bleeding during oral and dental procedures faces many challenges. The aim of this study was review strategies for facing high risk of bleeding patients taking dabigatran under dental procedure.
Methods: Articles and scientific texts will be searched in the six main databases, such as PubMed, Scopus, Web of Science, Science Direct, Google Scholar and Cochrane Library from 2007 to 2022, with keywords “dabigatran” AND “bleeding” AND “dental procedures” OR “dental care”. The inclusion criteria for articles included in the study were papers published about treatment patients with dabigatran and undergoing a dental procedure, English language and design of case reports, case series, quasi-experimental studies and clinical trials. This study was performed using PRISMA.
Results: At first, 43 references included and finally 8 articles that met the inclusion criteria were select. CASP and STORBE checklists used for quality evaluation. Two reviewers checked eligibility of the selected articles, separately. Challenging Controversial results were found in selected studies. 4 studies demonstrated that Dabigatran should be interrupted at least 12 hours before invasive dental procedures. Some studies highlight that discontinuing Dabigatran depends on the patient's renal function. Also, it showed that deciding whether to stop Dabigatran or not by cardiologists determine based on elective or emergency high-risk patients.
Conclusions: Based on the results of the included studies, it is better to decide to stop or continue dabigatran before any dental treatment based on the type of intervention, the risk of bleeding and the patient's clinical situation. However, is preferred to discontinue taking this drug in high risk of bleeding dental procedures.

[1] Randall C. Surgical management of the primary care dental patient on warfarin. Dent Update. 2005; 32(7):414-6, 9-20, 23-4 passim.
[2] Al-Mubarak S, Rass MA, Alsuwyed A, Alabdulaaly A, Ciancio S. Thromboembolic risk and bleeding in patients maintaining or stopping oral anticoagulant therapy during dental extraction. J Thromb Haemost. 2006; 4(3):689-91.
[3] Davie EW. A brief historical review of the waterfall/cascade of blood coagulation. Journal of Biological Chemistry. 2003; 278(51):50819-32.
[4] Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth. 2014;58(5):515-23.
[5] Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013; 52(2):69-82.
[6] Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants: opportunities and challenges. Arteriosclerosis, thrombosis, and vascular biology. 2015:ATVBAHA. 115.303397.
[7] Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, et al. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation. 2013;128(3):237-43.
[8] Truumees E, Gaudu T, Dieterichs C, Geck M, Stokes J. Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on Pradaxa (dabigatran). Spine (Phila Pa 1976). 2012; 37(14):E863-5.
[9] Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. The Lancet. 2007; 370(9591):949-56.
[10] Pollack CV. Evidence supporting idarucizumab for the reversal of dabigatran Am J Emerg Med. 2016; 129(11):S73-S9.
[11] Van Ryn J, Stangier J, Haertter S, Liesenfeld K-H, Wienen W, Feuring M, et al. Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 104(06):1116-27.
[12] Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med. 2011; 49(5):761-72.
[13] Wienen W, Stassen J-M, Priepke H, Ries UJ, Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007; 97(01):155-62.
[14] Breik O, Cheng A, Sambrook P, Goss A. Protocol in managing oral surgical patients taking dabigatran. Aust Dent J. 2014; 59(3):296-301.
[15] Davis C, Robertson C, Shivakumar S, Lee M. Implications of Dabigatran, a direct thrombin inhibitor, for oral surgery practice. J Can Dent Assoc. 2013; 79:d74.
[16] Hanken H, Gröbe A, Heiland M, Smeets R, Kluwe L, Wikner J, et al. Postoperative bleeding risk for oral surgery under continued rivaroxaban anticoagulant therapy. Clin Oral Investig. 2016;20(6):1279-82.
[17] Morimoto Y, Yokoe C, Mai Y, Sugihara M, Futatsuki T. Tooth extraction in patients taking nonvitamin K antagonist oral anticoagulants J Dent Sci. 2016; 11(1):59-64.
[18] Clemm R, Neukam FW, Rusche B, Bauersachs A, Musazada S, Schmitt CM. Management of anticoagulated patients in implant therapy: a clinical comparative study. Clin Oral Implants Res. 2016; 27(10):1274-82.
[19] Kwak EJ, Nam S, Park KM, Kim SY, Huh J, Park W. Bleeding related to dental treatment in patients taking novel oral anticoagulants (NOACs): a retrospective study. Clin Oral Investig. 2018; 1-8.
[20] Gomez-Moreno G, Fernandez-Cejas E, Aguilar-Salvatierra A, de Carlos F, Delgado-Ruiz RA, Calvo-Guirado JL. Dental implant surgery in patients in treatment by dabigatran. Clin Oral Implants Res. 2018; 29(6):644-648.
[21] Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al. Peri-procedural bleeding and thromboembolic events with dabigatran compared to warfarin: results from the RE-LY randomized trial. Circulation. 2012; 126(3):343-8.
[22] Hong CH, Islam I. Anti-Thrombotic Therapy: Implications for Invasive Outpatient Procedures in Dentistry. J Blood Disorders Transf. 2013; 4:166.
[23] van Diermen DE, van der Waal I, Hoogstraten J. Management recommendations for invasive dental treatment in patients using oral antithrombotic medication, including novel oral anticoagulants. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013; 116:709-16.
[24] yropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective pro-cedure or surgery. Blood. 2012; 120:2954-62.
[25] Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood. 2008; 111:4871-9.
[26] Curto A; Albaladejo A; Alvarado A. Dental management of patients taking novel oral anticoagulants (NOAs): dabigatran. J Clin Exp Dent; 2017, 9.2: e289.
[27] Schulman S, Carrier M, Lee AY, Shivakumar S, Blostein M, Spencer FA, et al. Perioperative Management of Dabigatran: A Prospective Cohort Study. Circulation. 2015;132(3):167-73.
[28] Elad S, Marshall J, Meyerowitz C, Connolly G. Novel anticoagulants: general overview and practical considerations for dental practitioners. Oral Dis. 2016;22(1):23-32.
[29] Beyer-Westendorf J, Gelbricht V, Forster K, Ebertz F, Kohler C, Werth S, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J. 2014;35(28):1888-96.
[30] Romond KK, Miller CS, Henry RG. Dental management considerations for a patient taking dabigatran etexilate: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013; 116(3):e191-5.
Files
IssueVol 10 No 3 (2024): Summer QRcode
SectionReview Article(s)
DOI https://doi.org/10.18502/aacc.v10i3.15698
Keywords
Dabigatran dental procedure high-risk bleeding
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Akbari H, Shahmoradi M, Bagheri A, Rogani Dehkordi N, Boostanifard P, Moradimajd P. Dabigatran and Dental Procedures in Patients with High Risk Bleeding. Arch Anesth & Crit Care. 2024;10(3):278-283.